Immune therapy developer Eledon Pharmaceuticals swings to Q3 net loss

Eledon Pharmaceuticals

14/11/2025 22:13

Overview

Eledon reports Q3 net loss of $17.46 mln, compared to net income last year

Company strengthens balance sheet with $57.5 mln financing for transplantation programs

Result Drivers

Research and development (R&D) expenses for the third quarter of 2025 were $15.0 million, including $1.1 million of non-cash stock-based compensation expense

FINANCIAL STRENGTH - $57.5 mln financing to advance transplantation programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$17.46 mln
Q3 Basic EPS
-$0.21
Q3 Income from Operations
-$19.07 mln
Q3 Operating Expenses
$19.07 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $9.00, about 80.4% above its November 13 closing price of $1.76

Press Release: ID:nGNX6cnv6y

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)